1. Stats
  2. USPTO
  3. TC 1600
  4. Group 1620
  5. Art Unit 1628
  6. Examiner Coppins

Examiner Coppins Janet L

1628-COPPINS-JANET-L

Employment Information

Art Unit:1628 — Drug, bio-affecting and body treating compositions
Group:1620 — Biomedicinal Chemistry
Classes: 514 — Drug, bio-affecting and body treating compositions
548 — Organic compounds -- part of the class 532-570 series
424 — Drug, bio-affecting and body treating compositions
604 — Surgery
544 — Organic compounds -- part of the class 532-570 series
607 — Surgery: light, thermal, and electrical application
549 — Organic compounds -- part of the class 532-570 series
128 — Surgery
568 — Organic compounds -- part of the class 532-570 series
504 — Plant protecting and regulating compositions
Phone:(571) 272-0680
Email:janet.coppins@uspto.gov
Location:VA 22314
Title:Pat Examnr Gen Chem
Service:24 years
Grade:GS-13

Grant Rate and Difficulty Ranking

73
3-Year Grant rate: 60% over 396 cases
Difficulty: Harder
Difficulty Percentile: 73rd

With Examiner Coppins, you have a 60% chance of getting an issued patent by 3 years after the first office action. Examiner Coppins is a harder examiner and in the 73rd percentile across all examiners (with 100th percentile most difficult).

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Coppins, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1628

Examiner Coppins's grant rate is higher than that of Art Unit 1628 and lower than that of the USPTO.

Average Office Actions Per Grant
Examiner Coppins 1.7
Art Unit 1628 1.7

Interview Benefit

Grant Rate without Interview

Examiner Coppins has granted 190 of 334 cases without any applicant-requested interviews for a grant rate of 57%.

Grant Rate with Interview

Examiner Coppins has granted 47 of 62 cases with at least one applicant-requested interview for a grant rate of 76%.

Interview Benefit

With Examiner Coppins, conducting an interview increases your chance of getting a patent granted by 33%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
17913471 2-Bromo-Lysergic Acid Diethylamide For Substance Abuse Rejection information available with a Premium Stats subscription. See our pricing. Patented View
18042010 Mitochondria-Targeted Antioxidant As Agent For Treating Pathologic Inflammation Caused By Mabc-R Infection Abandoned View
18620897 Method Of Treating Expressive Language Deficit In Autistic Humans Abandoned View
17166778 Method Of Treatment For Reducing Pain Sensitization Abandoned View
18628297 1-[2-(Aminomethyl)benzyl]-2-Thioxo-1,2,3,5-Tetrahydro-4h-Pyrrolo[3,2-D]pyrimidin-4-Ones As Inhibitors Of Myeloperoxidase Patented View
18618149 Orally Administered Combinations Of Amoxicillin And Avibactam Derivatives For Treating Mycobacterial Infections Abandoned View
17637713 Thixotropic Delivery Systems Abandoned View
18501268 Formulations For Substituted 3-Pyrrolidines, Compositions Containing, And Uses Of Same Abandoned View
17054054 Antibiotic Conjugates Patented View
17288385 Mucoadhesive Pharmaceutical Compositions Of Corticosteroids Patented View
17678340 Activity Of Gold-Complexed Compounds Against Mycobacterium Tuberculosis And Mycobacterium Abscessus Abandoned View
17447748 Parenteral Dosage Form Of Amiodarone Patented View
17524334 Nucleotide Analogs Patented View
18405453 Treatment Of Alopecia Areata Abandoned View
18333095 Ophthalmic Compositions Comprising Latanoprost For Use In The Treatment Of Ocular Diseases Abandoned View
17761187 Methods And Compositions For Tissue Regeneration Abandoned View
17021370 Methods For Reducing Or Preventing Cardiovascular Events In Patients With Type Ii Diabetes Mellitus Abandoned View
17245790 Fungicidal Compositions Comprising A Carboxamide Patented View
16781105 Compositions And Methods For The Improvement Of Memory Abandoned View
18545961 Polymorphic Forms Of St-246 And Methods Of Preparation Patented View
18481522 Stat3 Inhibitors Abandoned View
17373296 Long Acting Multi-Specific Molecules And Related Methods Patented View
18549148 Compositions And Methods For Improving Brain Function Abandoned View
17937743 Compositions For Non-Surgical Prevention Of Boar Taint And Aggressive Behavior Abandoned View
16962541 Veterinary Antiprolactinic Composition Abandoned View
17393210 Inhibition Of Microsomal Prostaglandin E2 (Pge2) Synthase-1 (Mpges-1) Abandoned View
17905549 Compounds For Use In A Method Of Treating, Preventing And/or Reducing The Symptoms Of Pain Abandoned View
17825777 Therapeutic Methods, Combinations And Kits Patented View
17523806 Nucleotide Analogs Patented View
16337698 Compounds For Increasing Neural Plasticity Patented View
17487473 Pac-1 Combination Therapy Patented View
17682165 Metap2 Inhibitors And Methods Of Treating Obesity Abandoned View
16746050 The Use Of Lipophilic Beta-Lactam Antibiotics And Carboxylate Esters For The Treatment Of Bacterial Infections Within Citrus And Other Plant Species Patented View
18295654 Topical Montelukast For Treatment Of Atopic Dermatitis Abandoned View
17474581 Methods Of Using Ehmt2 Inhibitors Abandoned View
18188691 Combination Therapies With Ehmt2 Inhibitors Abandoned View
17862656 Methods And Compositions For The Prevention And Treatment Of Hearing Loss Patented View
18213013 Devices And Methods For Delivery Of Oxygen To A Wound Abandoned View
17653056 Therapeutic Combinations Abandoned View
18369455 1-Deoxynojirimycin To Mitigate Hepatic Ischemia- Reperfusion Abandoned View
18080732 Pyrrolidine Derivative And Use Thereof Patented View
18085842 Stable Pharmaceutical Composition For Oral Administration Abandoned View
17255364 The Use Of Repirinast In The Prophylaxis Or Treatment Of Renal Fibrosis Or Kidney Disease Patented View
16768615 Methods And Materials For Assessing Biological Age And Slowing The Progress Of Excessive Biological Aging Abandoned View
17712566 Compounds And Methods For Delivery Of Prostacyclin Analogs Abandoned View
17492136 Intranasal Delivery Of Dihydroergotamine By Precision Olfactory Device Abandoned View
17829147 Nucleotide Analogs Abandoned View
17508202 Prevention Of Atherosclerotic Events With Direct Factor Xa Inhibitors Abandoned View
17148785 Azetidine Derivatives Patented View
17378346 Mono- And Di-Amidine Endo-Exonuclease Inhibitors And Methods For Inhibiting Endo-Exonuclease Activity Patented View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.